Law360, New York (April 30, 2012, 5:40 PM EDT) -- A New Jersey federal judge on Monday held that two generic anti-acne drugs made by Mylan Pharmaceuticals Inc. and Impax Laboratories Inc. do not infringe a patent for Warner Chilcott Co. LLC’s brand-name drug Doryx, but refused to find a Doryx patent invalid.
Doryx is manufactured by Mayne Pharma Group but is marketed by Warner Chilcott, the suit says.
U.S. District Judge William J. Martini ruled that Warner Chilcott didn’t prove that Mylan’s and Impax’s pills contain a stabilizing coat, as specified by Mayne’s patent....
Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.